A cohort study found that nearly three fourths of infants received respiratory syncytial virus protection with either nirsevimab or through exposure to maternal RSVpreF in the 2023-2024 season.

It is the first approval for Beyfortus (nirsevimab) by any regulatory authority. AZ's Synagis (palivizumab) is currently the only approved drug in Europe to provide passive prophylaxis against RSV ...

At a meeting to present its vaccines pipeline to investors today, the French pharma is highlighting the potential of Beyfortus (nirsevimab) for the protection of infants in their first RSV season ...

A study today in JAMA Network Open from the University of California, San Francisco (UCSF), shows a high uptake of respiratory syncytial virus (RSV) vaccine and the RSV-preventing monoclonal antibody ...

And then the study also looked at the uptake of nirsevimab, which is that monoclonal antibody given to infants to protect against RSV. Among the pregnant individuals who did not receive the RSV ...

The immunization schedule protects against 14 potentially serious diseases before a child’s second birthday, as recommended ...

Hamilton families have one last chance to get their babies immunized against a common virus that can cause serious lung infections before a clinic at McMaster Children’s Hospital closes. The last ...

Treatment changes of any kind were recommended in 54% of cases. Cancer patients who sought a second opinion via a virtual platform received a recommendation for a treatment change more than half ...

U.K. Prime Minister Pledges More European Support for Ukraine After a summit of European leaders in London, Prime Minister Keir Starmer of Britain said a “coalition of the willing” would be ...